RSVPreF3 OA investigational vaccine

Phase 3Vaccine

RSVPreF3 OA investigational vaccine is one of 6 therapeutic programs targeting Respiratory Syncytial Virus Infections. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Respiratory Syncytial Virus InfectionsActive, not recruiting

Respiratory Syncytial Virus InfectionsPhase 3

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Respiratory Syncytial Virus Infections

#DrugCompanyPhaseTrials

Rsvpref3 Vaccine

GSK

Phase 3

4 2

Rsvpref3 OA Vaccine

GSK

Phase 3

2 3

RSVPreF3 OA investigational vaccine

GSK

Phase 3

2 4

Adjuvanted Rsvpref3 Vaccine

GSK

Phase 2

1 5

S-337395

Shionogi

Phase 2

1 6

Ziresovir

SShanghai Ark Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Respiratory Syncytial Virus Infections

NCT04732871

Clinical

Trials by Indication[1]

Respiratory Syncytial Virus Infections2 trials

A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above

Active, not recruiting· GSK logo

GSK·Phase 3·NCT04732871·1,720 enrolled

A Phase 3, Randomized, Placebo-controlled, Observer-blind Study in India to Evaluate Immune Response, Reactogenicity and Safety of a Single Intramuscular Dose of RSVPreF3 OA Investigational Vaccine When Administered to Older Adults >=60 Years of Age and Adults 50-59 Years of Age at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease

Completed· GSK logo

GSK·Phase 3·NCT06614725·751 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for RSVPreF3 OA investigational vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for RSVPreF3 OA investigational vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine
Highest Phase: Phase 3[1]
Company: GSK

RSVPreF3 OA investigational vaccine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Respiratory Syncytial Virus Infections2 trials

References

Drug Info

Quick Facts

Related News